Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients

Qing Ma, Harris A. Gelbard, Sanjay B. Maggirwar, Stephen Dewhurst, Howard Eliot Gendelman, Derick R. Peterson, Robin Difrancesco, Jill S. Hochreiter, Gene D. Morse, Giovanni Schifitto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

CEP-1347 is a potent inhibitor of mixed lineage kinase (MLK), which was investigated for ameliorating HIV-associated neurocognitive disorders. CEP-1347 and atazanavir pharmacokinetics were determined when CEP-1347 50 mg twice daily was administered to HIV-infected patients (n = 20) receiving combination antiretroviral therapy including atazanavir and ritonavir (ATV/RTV, 300/100 mg) once daily continuously. Co-administration of CEP-1347 and ATV/RTV resulted with significant changes in pharmacokinetics of ATV but not RTV. Specifically, an increase in ATV accumulation ratio of 15 % (p = 0.007) and a prolongation of T 1/2 from 12.7 to 15.9 h (p = 0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalJournal of neurovirology
Volume19
Issue number3
DOIs
StatePublished - Jun 1 2013

Fingerprint

Pharmacokinetics
HIV
Ritonavir
Phosphotransferases
3,9-bis((ethylthio)methyl)-K-252a
Atazanavir Sulfate
Therapeutics

Keywords

  • Atazanavir
  • CEP-1347
  • Drug interactions
  • HIV
  • Mixed lineage kinases
  • Ritonavir

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Ma, Q., Gelbard, H. A., Maggirwar, S. B., Dewhurst, S., Gendelman, H. E., Peterson, D. R., ... Schifitto, G. (2013). Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. Journal of neurovirology, 19(3), 254-260. https://doi.org/10.1007/s13365-013-0172-z

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. / Ma, Qing; Gelbard, Harris A.; Maggirwar, Sanjay B.; Dewhurst, Stephen; Gendelman, Howard Eliot; Peterson, Derick R.; Difrancesco, Robin; Hochreiter, Jill S.; Morse, Gene D.; Schifitto, Giovanni.

In: Journal of neurovirology, Vol. 19, No. 3, 01.06.2013, p. 254-260.

Research output: Contribution to journalArticle

Ma, Q, Gelbard, HA, Maggirwar, SB, Dewhurst, S, Gendelman, HE, Peterson, DR, Difrancesco, R, Hochreiter, JS, Morse, GD & Schifitto, G 2013, 'Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients', Journal of neurovirology, vol. 19, no. 3, pp. 254-260. https://doi.org/10.1007/s13365-013-0172-z
Ma, Qing ; Gelbard, Harris A. ; Maggirwar, Sanjay B. ; Dewhurst, Stephen ; Gendelman, Howard Eliot ; Peterson, Derick R. ; Difrancesco, Robin ; Hochreiter, Jill S. ; Morse, Gene D. ; Schifitto, Giovanni. / Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. In: Journal of neurovirology. 2013 ; Vol. 19, No. 3. pp. 254-260.
@article{ac2ee760ed2c45979fb23079dc70583e,
title = "Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients",
abstract = "CEP-1347 is a potent inhibitor of mixed lineage kinase (MLK), which was investigated for ameliorating HIV-associated neurocognitive disorders. CEP-1347 and atazanavir pharmacokinetics were determined when CEP-1347 50 mg twice daily was administered to HIV-infected patients (n = 20) receiving combination antiretroviral therapy including atazanavir and ritonavir (ATV/RTV, 300/100 mg) once daily continuously. Co-administration of CEP-1347 and ATV/RTV resulted with significant changes in pharmacokinetics of ATV but not RTV. Specifically, an increase in ATV accumulation ratio of 15 {\%} (p = 0.007) and a prolongation of T 1/2 from 12.7 to 15.9 h (p = 0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics.",
keywords = "Atazanavir, CEP-1347, Drug interactions, HIV, Mixed lineage kinases, Ritonavir",
author = "Qing Ma and Gelbard, {Harris A.} and Maggirwar, {Sanjay B.} and Stephen Dewhurst and Gendelman, {Howard Eliot} and Peterson, {Derick R.} and Robin Difrancesco and Hochreiter, {Jill S.} and Morse, {Gene D.} and Giovanni Schifitto",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s13365-013-0172-z",
language = "English (US)",
volume = "19",
pages = "254--260",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients

AU - Ma, Qing

AU - Gelbard, Harris A.

AU - Maggirwar, Sanjay B.

AU - Dewhurst, Stephen

AU - Gendelman, Howard Eliot

AU - Peterson, Derick R.

AU - Difrancesco, Robin

AU - Hochreiter, Jill S.

AU - Morse, Gene D.

AU - Schifitto, Giovanni

PY - 2013/6/1

Y1 - 2013/6/1

N2 - CEP-1347 is a potent inhibitor of mixed lineage kinase (MLK), which was investigated for ameliorating HIV-associated neurocognitive disorders. CEP-1347 and atazanavir pharmacokinetics were determined when CEP-1347 50 mg twice daily was administered to HIV-infected patients (n = 20) receiving combination antiretroviral therapy including atazanavir and ritonavir (ATV/RTV, 300/100 mg) once daily continuously. Co-administration of CEP-1347 and ATV/RTV resulted with significant changes in pharmacokinetics of ATV but not RTV. Specifically, an increase in ATV accumulation ratio of 15 % (p = 0.007) and a prolongation of T 1/2 from 12.7 to 15.9 h (p = 0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics.

AB - CEP-1347 is a potent inhibitor of mixed lineage kinase (MLK), which was investigated for ameliorating HIV-associated neurocognitive disorders. CEP-1347 and atazanavir pharmacokinetics were determined when CEP-1347 50 mg twice daily was administered to HIV-infected patients (n = 20) receiving combination antiretroviral therapy including atazanavir and ritonavir (ATV/RTV, 300/100 mg) once daily continuously. Co-administration of CEP-1347 and ATV/RTV resulted with significant changes in pharmacokinetics of ATV but not RTV. Specifically, an increase in ATV accumulation ratio of 15 % (p = 0.007) and a prolongation of T 1/2 from 12.7 to 15.9 h (p = 0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics.

KW - Atazanavir

KW - CEP-1347

KW - Drug interactions

KW - HIV

KW - Mixed lineage kinases

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=84879823912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879823912&partnerID=8YFLogxK

U2 - 10.1007/s13365-013-0172-z

DO - 10.1007/s13365-013-0172-z

M3 - Article

VL - 19

SP - 254

EP - 260

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 3

ER -